Literature DB >> 7705408

Major histocompatibility complex class I-restricted presentation of influenza virus nucleoprotein peptide by B lymphoma cells harboring an antibody gene antigenized with the virus peptide.

R Billetta1, G Filaci, M Zanetti.   

Abstract

We analyzed the capacity of B cells to process and present a peptide from the variable region of an endogenous immunoglobulin heavy (H) chain to a major histocompatibility complex (MHC) class I-restricted cytotoxic T lymphocyte (CTL) clone. The H-chain gene was engineered to express 14-amino acid peptide from the sequence of the influenza virus nucleoprotein (NP) antigen in the third complementarity-determining region (CDR3). This NP peptide is presented in association with the Db allele in H-2b mice. We demonstrate that B lymphoma cells (H-2b) harboring the antigenized H-chain gene process and present the NP peptide in association with the Db molecule and are lysed by a CTL clone specific for that peptide in an MHC-restricted way. In contrast, the soluble antigenized antibody failed to mediate lysis of H-2b target cells. The endogenously processed immunoglobulin CDR3 peptide could be eluted from surface Db molecules in transfected cells. This study formally demonstrates that peptides from the hypervariable loops of endogenous immunoglobulin are processed through the endogenous degradative pathway and are presented to CD8+ T cells in the context of MHC class I molecules. The implication of these findings for processing and presentation of endogenous immunoglobulin peptides in B cells and network regulation by idiopeptides is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7705408     DOI: 10.1002/eji.1830250323

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  The principle of delivery of T cell epitopes to antigen-presenting cells applied to peptides from influenza virus, ovalbumin, and hen egg lysozyme: implications for peptide vaccination.

Authors:  I B Rasmussen; E Lunde; T E Michaelsen; B Bogen; I Sandlie
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Phage-displayed T-cell epitope grafted into immunoglobulin heavy-chain complementarity-determining regions: an effective vaccine design tested in murine cysticercosis.

Authors:  K Manoutcharian; L I Terrazas; G Gevorkian; G Acero; P Petrossian; M Rodriguez; T Govezensky
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  In vivo role of B lymphocytes in somatic transgene immunization.

Authors:  S Xiong; M Gerloni; M Zanetti
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

4.  A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells.

Authors:  Melissa Santone; Susanna Aprea; Tom Y H Wu; Michael P Cooke; M Lamine Mbow; Nicholas M Valiante; James S Rush; Stephanie Dougan; Ana Avalos; Hidde Ploegh; Ennio De Gregorio; Cecilia Buonsanti; Ugo D'Oro
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease.

Authors:  William F Pendergraft; Barrak M Pressler; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  J Mol Med (Berl)       Date:  2004-12-11       Impact factor: 4.599

6.  T cell immunity using transgenic B lymphocytes.

Authors:  Mara Gerloni; Marta Rizzi; Paola Castiglioni; Maurizio Zanetti
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-02       Impact factor: 11.205

Review 7.  Immunogenic properties of immunoglobulin superfamily members within complex biological networks.

Authors:  Josué Odales; Jesus Guzman Valle; Fernando Martínez-Cortés; Karen Manoutcharian
Journal:  Cell Immunol       Date:  2020-10-11       Impact factor: 4.868

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.